Title
Whole genome sequencing identifies bacterial factors affecting transmission of multidrug-resistant tuberculosis in a high-prevalence setting
Date Issued
01 December 2019
Access level
open access
Resource Type
journal article
Author(s)
Dixit A.
Freschi L.
Vargas R.
Sacchettini J.
Drobniewski F.
Galea J.T.
Contreras C.
Zhang Z.
Kolokotronis S.O.
Mathema B.
Farhat M.R.
Publisher(s)
Nature Publishing Group
Abstract
Whole genome sequencing (WGS) can elucidate Mycobacterium tuberculosis (Mtb) transmission patterns but more data is needed to guide its use in high-burden settings. In a household-based TB transmissibility study in Peru, we identified a large MIRU-VNTR Mtb cluster (148 isolates) with a range of resistance phenotypes, and studied host and bacterial factors contributing to its spread. WGS was performed on 61 of the 148 isolates. We compared transmission link inference using epidemiological or genomic data and estimated the dates of emergence of the cluster and antimicrobial drug resistance (DR) acquisition events by generating a time-calibrated phylogeny. Using a set of 12,032 public Mtb genomes, we determined bacterial factors characterizing this cluster and under positive selection in other Mtb lineages. Four of the 61 isolates were distantly related and the remaining 57 isolates diverged ca. 1968 (95%HPD: 1945ā1985). Isoniazid resistance arose once and rifampin resistance emerged subsequently at least three times. Emergence of other DR types occurred as recently as within the last year of sampling. We identified five cluster-defining SNPs potentially contributing to transmissibility. In conclusion, clusters (as defined by MIRU-VNTR typing) may be circulating for decades in a high-burden setting. WGS allows for an enhanced understanding of transmission, drug resistance, and bacterial fitness factors.
Volume
9
Issue
1
Language
English
OCDE Knowledge area
Sistema respiratorio
GenƩtica humana
Enfermedades infecciosas
Scopus EID
2-s2.0-85063934865
PubMed ID
Source
Scientific Reports
ISSN of the container
20452322
Sponsor(s)
We thank Megan Murray, the co-PI of the Peru Epi study for helpful input on the manuscript. We thank the patients and their families who contributed to this study. We also thank the Partners in Health healthcare personnel at participating health centers in Lima, Peru. We wish to thank Dr. Robert Husson for his invaluable feedback on an initial draft of the manuscript. The study was funded by the National Institutes of Health (Peru Epi study U19-AI076217 and K01-ES026835 to MRF) and The Welch Foundation (A-0015 to JS). The funding sources had no role in any aspect of the study, manuscript or decision to submit it for publication.
Sources of information:
Directorio de Producción CientĆfica
Scopus